1. Home
  2. Age-Related Macular Degeneration (ARMD) Doctors Near Me
  3. Clinical Trials
  4. Prognostic Role of Macular Neovascular Membrane Subtype in Pneumatic Displacement of Macular Hemorrhages

Age-Related Macular Degeneration (ARMD) Clinical Trials

Find Age-Related Macular Degeneration (ARMD) Clinical Trials Near You

Find a DoctorCondition OverviewLatest AdvancesClinical TrialsTreatments

Prognostic Role of Macular Neovascular Membrane Subtype in Pneumatic Displacement of Macular Hemorrhages

Status: Recruiting
Location: See location...
Study Type: Observational
SUMMARY

This study investigates the prognostic value of macular neovascularization (MNV) subtypes in patients treated with pneumatic displacement for submacular hemorrhage. The researchers will compare anatomical and functional outcomes (visual acuity) between PCV, RAP, and other MNV forms within a Caucasian cohort to identify subtype-specific predictors of recovery.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 50
Healthy Volunteers: f
View:

• Patients undergoing pneumatic displacement (PD) for submacular hemorrhage (SMH), secondary to macular neovascularization (MNV)

• Age 50 years or older at the time of SMH diagnosis

• Caucasian ethnicity

• SMH involving the central or internal ring of the Early Treatment Diabetic Retinopathy Study (ETDRS) grid (within a 3 mm circumference centered on the fovea)

• SMH dimensions equal to or greater than one papillary diameter

• Pneumatic displacement treatment performed within 36 hours of SMH diagnosis

Locations
Other Locations
Italy
Ospedale Santa Chiara Di Trento
RECRUITING
Trento
Contact Information
Primary
marco mazzola, medical doctor
marco.mazzola@asuit.tn.it
+393479950266
Backup
tommaso brighenti, MD
tommaso.brighenti@asuit.tn.it
+393484780821
Time Frame
Start Date: 2025-10-15
Estimated Completion Date: 2026-12-15
Participants
Target number of participants: 60
Treatments
PCV
Patients with submacular hemorrhage secondary to Polypoidal Choroidal Vasculopathy (PCV)
RAP
Patients with submacular hemorrhage secondary to Retinal Angiomatous Proliferation (RAP), also known as Type 3 MNV
Other MNV
Patients with submacular hemorrhage secondary to other forms of Macular Neovascularization (MNV) not classified as PCV or RAP
Related Therapeutic Areas
Age-Related Macular Degeneration (ARMD)
Late-Onset Retinal Degeneration
Sponsors
Leads: Marco Mazzola

This content was sourced from clinicaltrials.gov

Similar Clinical Trials

Age-Related Macular Degeneration Benchmark Imaging Dataset (ABID)

Age-Related Macular Degeneration Benchmark Imaging Dataset (ABID)

Enrollment Status: Recruiting
Publish Date: March 27, 2026
Intervention Type: Other

Full Thickness Macular Hole; Should it be Handled Subacutely?

Full Thickness Macular Hole; Should it be Handled Subacutely?

Enrollment Status: Recruiting
Publish Date: April 16, 2024
Intervention Type: Procedure
Study Phase: Not Applicable

Progression of Early Atrophic Lesions in Age-related Macular Degeneration (AMD).

Progression of Early Atrophic Lesions in Age-related Macular Degeneration (AMD).

Enrollment Status: Recruiting
Publish Date: March 11, 2026
Intervention Type: Other
View All
For Patients
  • Our Story
  • How MediFind Works
  • Conditions A-Z
  • Doctor Directory
  • Symptoms Directory
  • Procedures Directory
  • Treatment Directory
  • Drug Directory
  • Infusion Center Finder
  • FAQ
  • Contact Us
For Providers and Practices
  • Claim Your Profile
  • Newsroom
Business Solutions
  • Provider
  • Network Solutions
Additional Resources
  • Consumer Health Data Privacy Policy
  • Privacy Policy
  • Terms of Use
  • Advertising Policy
  • Content Policy
Subscribe to our newsletter

Sign up to stay informed about MediFind and get wellness sent your way.

Close

    By subscribing, I agree to MediFind's Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.

    Bullet PinMediFind
    Follow us on
    This information is not intended as a substitute for informed medical advice. You should work with a licensed professional to diagnose and treat health conditions. We let the data speak for itself, MediFind does not endorse any healthcare providers.
    © 2026 All Rights Reserved